Ultragenyx Pharmaceutical RARE Institutional Ownership

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has 309 institutional investors that have filed 13F reports for the period ending June 2026.

• These investors collectively held 105.4% of Ultragenyx Pharmaceutical's outstanding shares in June 2026, up from 97.5% in March 2026.
• They increased total shares held in RARE by 15.37% quarter over quarter, and investors in Ultragenyx Pharmaceutical increased 0.65% from a year ago.
• Activity in RARE broke down as 173 buyers, 98 sellers, and 38 unchanged among 309 total holders.
• Altogether, these fund groups held 107.44Mn shares in RARE by June 2026, up by 14.31Mn shares quarter on quarter, and up 14.09Mn shares year over year.
• BlackRock, Inc. is the top holder of Ultragenyx Pharmaceutical as of June 30, 2026, with 10.65Mn shares representing 10.46% of outstanding stock.
• The biggest buyers of Ultragenyx Pharmaceutical for the quarter ending June 2026 included RTW INVESTMENTS, LP (4.15Mn), BlackRock, Inc. (3.35Mn), AQR CAPITAL MANAGEMENT LLC (1.98Mn), JACOBS LEVY EQUITY MANAGEMENT, INC (1.51Mn), MPM BioImpact LLC (1.42Mn).
• The largest sellers of Ultragenyx Pharmaceutical for the quarter ending June 2026 were Assenagon Asset Management S.A. (2.14Mn), CITADEL ADVISORS LLC (1.9Mn), Sofinnova Investments, Inc. (1.43Mn), WELLINGTON MANAGEMENT GROUP LLP (1.39Mn), MILLENNIUM MANAGEMENT LLC (1.01Mn).
• Business Quant data shows the 10 biggest positions in Ultragenyx Pharmaceutical as of June 2026 are held by BlackRock, Inc. (10.65Mn), RTW INVESTMENTS, LP (7.8Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (6.79Mn), AQR CAPITAL MANAGEMENT LLC (6.56Mn), State Street Corp (6.16Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.3Mn), TWO SIGMA INVESTMENTS, LP (3.62Mn), SANDS CAPITAL MANAGEMENT, LLC (3.16Mn), JACOBS LEVY EQUITY MANAGEMENT, INC (2.94Mn), FRONTIER CAPITAL MANAGEMENT CO LLC (2.85Mn).